Table s5. PICO 3: Should rapid serology (capillary blood) vs. standard serology (venous blood) be used to detect SARS-CoV-2 antibodies

Study	COVID-19 patients	Control group	Index Test	Reference Standard
Prazuck (2020)[1] France Cohort Study	**N: 381 Total patients (Cohort Design) (238/381) (62.47%)** **Inclusion**: Patients with symptoms of COVID-19 (headache, fatigue, fever or respiratory signs) who tested positive on RT-PCR **Exclusion**: NR **Age**: mean age was 48.20 years (SD: 17.00; range 19-72), and median at 46 years **Gender**: NR **Disease severity: NR** **Asymptomatic: NR**	**N: 381 Total patients (Cohort Design) (143/382) (37.53%)** **Inclusion:** Patients with symptoms of COVID-19 (headache, fatigue, fever or respiratory signs) who tested negative on RT-PCR **Exclusion**: NR **Age**: mean age of patients was 53.68 years ± 20.18 (median 54; range 19-96) **Gender**: NR	**Timing:** data presented as days between onset of symptoms and sample collection 0-5 days (20); 6-10 days (43); 11-15 days (39); >15 (48) **1. COVID PRESTO** - Platform: LF, Fingertip Blood. - Antibody type: IgM/IgG - Antibodies target: COVID DUO - Approval: NR **2. COVID DUO** - Platform: LF, Fingertip Blood - Antibody type: IgM/ IgG - Antibodies target: COVID DUO - Approval: NR	**RT-PCR, nasopharyngeal swabs** - Day performed: NR - Platform: NR - Target: RNA-dependent RNA polymerases (IP2 and IP4) and E genes
Pellanda (2020)[2] Brazil Case-Control	**N: 83** **Inclusion**: Adult patients with PCR (+) on NP swab during March 2020. These patients were invited to participate in the study at least 10 days after positive PCR. **Exclusion**: NR **Age**: Mean age 48.6 (SD = 14.4) **Gender**: 53% males **Disease severity: NR** **Asymptomatic:** Symptomatic or asymptomatic at the time of testing.	**N: 100 (not clear if capillary or venous blood)** **Inclusion:** pre-COVID-19 serum collection from individuals belonging to the 1982 Birth Cohort Study **Exclusion**: NR **Age**: Mean age 30.0 (SD = 0.3) years. **Gender**: 37% Males	**Timing:** data presented for at least 10 days after positive RT-PCR **1. Wondfo SARS-CoV-2 Antibody Test (Lateral Flow Method (15 minutes)** - Platform: LF, Fingertip Blood. - Antibody type: IgM/IgG - Antibodies target: NR - Approval: NR	**RT-PCR on nasal swab** - Day performed: NR - Platform: NR - Target: NR

Study	COVID-19 patients	Control group	Index Test	Reference Standard
Black (2020)[3] USA Case-Control	**N: 14** **Inclusion**: Patients with COVID-19 diagnosis based on PCR (+) **Exclusion**: NR **Age**: NR **Gender**: NR **Disease severity: NR** **Asymptomatic:** NR	**N: No control for capillary blood.**	**Timing:** 14 days from both symptom onset (range, 19-61 days; median, 32 days) and PCR diagnosis (range, 18-46 days; median, 30.5 days). **1. IgG/IgM Detection Kit (Colloidal Gold) (Biolidics Ltd., Singapore)** - Platform: LF, Fingertip Blood. - Antibody type: IgM/IgG - Antibodies target: NR - Approval: NR	**Cobas Covid-19 Rt-PCR on nasal swab** - Day performed: NR - Platform: NR - Target: NR
Vibrant America Clinical Labs Vibrant COVID-19 Ab (Insert)[4]	**N: 158** **Inclusion**: COVID-19 suspected patients with both dried blood spot and serum samples. **Exclusion**: NR **Age**: NR **Gender**: NR **Disease severity: NR** **Asymptomatic:** NR	**Control:** COVID-19 suspected patients with both dried blood spot and serum samples.	**Timing:** Samples were collected 4 to 26 days after NP swab collection. (median 14 days) **1. Vibrant COVID-19 Ab Assay** - Platform: CIA - Antibody type: IgM/IgG - Antibodies target: S, N protein - Approval: EUA	**Serum vs Dried blood spot:** **52/52 positive in both,** **106/106 negative in both** **DTA Results:** **(not included in the analysis)** **IgM sensitivity: 49/53 (92%)** **IgM specificity: 104/105 (99%)** **IgG sensitivity: 51/52 (96%)** **IgG specificity: 104/105 (99%)**